Zoetis Inc. $ZTS Shares Acquired by Fifth Third Wealth Advisors LLC

Fifth Third Wealth Advisors LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,323 shares of the company’s stock after buying an additional 802 shares during the quarter. Fifth Third Wealth Advisors LLC’s holdings in Zoetis were worth $1,454,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Fulcrum Capital LLC lifted its stake in Zoetis by 7.3% during the second quarter. Fulcrum Capital LLC now owns 56,393 shares of the company’s stock worth $8,794,000 after purchasing an additional 3,847 shares during the last quarter. Summit Place Financial Advisors LLC lifted its stake in Zoetis by 0.8% during the second quarter. Summit Place Financial Advisors LLC now owns 19,293 shares of the company’s stock worth $3,009,000 after purchasing an additional 149 shares during the last quarter. Aberdeen Group plc lifted its stake in Zoetis by 5.4% during the second quarter. Aberdeen Group plc now owns 1,155,604 shares of the company’s stock worth $179,720,000 after purchasing an additional 59,245 shares during the last quarter. Davis Rea LTD. lifted its stake in Zoetis by 96.6% during the second quarter. Davis Rea LTD. now owns 41,239 shares of the company’s stock worth $6,431,000 after purchasing an additional 20,268 shares during the last quarter. Finally, Blue Zone Wealth Advisors LLC lifted its stake in Zoetis by 8.8% during the second quarter. Blue Zone Wealth Advisors LLC now owns 32,626 shares of the company’s stock worth $5,088,000 after purchasing an additional 2,646 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $141.05 on Friday. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The business has a 50 day simple moving average of $149.24 and a 200-day simple moving average of $154.41. The stock has a market capitalization of $62.51 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.26 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the business earned $1.56 earnings per share. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is 34.42%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ZTS shares. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.